Validity of Research in Asset Management

Subscribe to newsletter

Academic and practitioners’ literature is a source for many investment and trading ideas. However, it is often criticized for producing ideas that do not work in practice. A problem we have seen repeatedly is that the published papers, more often than not, only present in-sample results and disregard out-of-sample ones. This is an important distinction that is often overlooked.

In-sample results are generated by using the same data to estimate a model and then using the estimated model to make predictions. This approach can produce seemingly good results, but the model may not perform well when applied to new data. Out-of-sample results are generated by using a part of the data to estimate the model and then using the estimated model to make predictions for the remaining data. This approach provides a more accurate assessment of the model’s predictive power.

Reference [1] presented an overview of the literature and it confirmed the problem of in-sample overfitting in asset management research. It also provided insights into the quality of research conducted by practitioners,

Subscribe to newsletter https://harbourfrontquant.beehiiv.com/subscribe Newsletter Covering Trading Strategies, Risk Management, Financial Derivatives, Career Perspectives, and More

I believe p-hacking is less of a problem in asset management than in academia—in particular, less of a problem in the proprietary research that is the foundation for a product. The reasons are simple. First, in the presence of a performance fee, the asset management company’s research needs to be optimized in a way that maximizes the chances of repeatable performance (see Harvey and Liu (2018)). This means the asset manager does not choose the best-performing backtest, because likely it resulted from overfitting and luck. If the manager were to launch a backtest-overfitted strategy, it would likely fail and generate no performance fees. The second reason is reputation. Academic tenure has no equivalent in asset management. If an asset manager’s products disappoint because of overfitting, the firm’s investors will flee. This market mechanism naturally minimizes the overfitting. That said, asset management companies still produce a substantial amount of low-quality research. Similar to the academic research, investors need to be skeptical.

In short, in-sample overfitting is less of a problem in proprietary research than in academic research. Regardless, investors should be skeptical of both types of research results.

Let us know what you think in the comments below.

References

[1] Harvey, Campbell R., The Pitfalls of Asset Management Research (2022). https://ssrn.com/abstract=4078138

Subscribe to newsletter https://harbourfrontquant.beehiiv.com/subscribe Newsletter Covering Trading Strategies, Risk Management, Financial Derivatives, Career Perspectives, and More

Further questions

What's your question? Ask it in the discussion forum

Have an answer to the questions below? Post it here or in the forum

LATEST NEWSBlue Moon Announces Robust Results of the Preliminary Economic Assessment for Its Blue Moon VMS Deposit Including an After-Tax Base Case IRR of 38% and 48% Using Spot Prices
Blue Moon Announces Robust Results of the Preliminary Economic Assessment for Its Blue Moon VMS Deposit Including an After-Tax Base Case IRR of 38% and 48% Using Spot Prices

TORONTO, March 03, 2025 (GLOBE NEWSWIRE) — Blue Moon Metals Inc. (“Blue Moon” or the “Company”) (TSXV: MOON), is pleased to announce an updated Mineral Resource estimate and the results of a Preliminary Economic Assessment (“PEA”) for the Blue Moon volcanogenic massive sulphide (“VMS”) deposit…

Stay up-to-date with the latest news - click here
LATEST NEWSProtagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were…

Stay up-to-date with the latest news - click here
LATEST NEWSUK net mortgage lending rises by most since September 2022
UK net mortgage lending rises by most since September 2022
Stay up-to-date with the latest news - click here
LATEST NEWSEx-Barclays CEO Staley should be banned over Epstein statements, UK's FCA says
Ex-Barclays CEO Staley should be banned over Epstein statements, UK's FCA says
Stay up-to-date with the latest news - click here
LATEST NEWSGhana lawmakers reintroduce anti-LGBTQ legislation
Ghana lawmakers reintroduce anti-LGBTQ legislation
Stay up-to-date with the latest news - click here

Leave a Reply